HCG, a leading provider of cancer care in India, announced its financial results for the fourth quarter (Q4FY24) and the full fiscal year 2024 (FY24), showcasing strong growth and profitability.
Q4FY24 Financial Highlights:
Revenue: ₹4,946 million (12% YoY growth)
Adjusted EBITDA: ₹941 million (21% YoY growth)
PAT: ₹213 million (154% YoY growth)
FY24 Financial Highlights:
Revenue: ₹19,121 million (13% YoY growth)
Adjusted EBITDA: ₹3,374 million (11% YoY growth)
PAT: ₹482 million (65% YoY growth)
Business Updates for Q4 FY24:
Overall ARPOB: ₹41,802 (10% growth compared to Q4 FY23)
Overall AOR: 64.2% (compared to 65.4% in Q4 FY23)
RoCE (Q4FY24 Annualized):
Established centers: 20.6% (compared to 20.9% in FY23)
Emerging centers: -2.9% (compared to -4.9% in FY23)
Regional Growth: Several regions achieved double-digit revenue growth YoY.
South Mumbai and Kolkata grew by 37% and 20% YoY, respectively.
Nagpur, Baroda, and Vizag grew by 48%, 26%, and 23% YoY, respectively.
Management Commentary:
Dr. B.S. Ajaikumar, Executive Chairman of HCG, expressed satisfaction with the consistent benchmark-beating performance across all fronts for the quarter and the fiscal year. The company attributes its success to its unique value-based care model, focused factory approach, and commitment to providing affordable and quality cancer care across India.
Key Takeaways:
Strong financial performance in Q4FY24 and FY24, driven by increased revenue, adjusted EBITDA, and PAT.
Significant growth in several key regions, including South Mumbai, Kolkata, Nagpur, Baroda, and Vizag.
Continued focus on enhancing operations, improving profitability, and expanding through strategic acquisitions.
For more information, you can refer to:
HCG Investor Relations: https://www.hcgoncology.com/investor-relations/
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/healthcare-global-enterprises-ltd
5paisa Share Price: https://www.5paisa.com/stocks/hcg-share-price
Kommentare